NIH National Cancer Institute (NCI)
Outstanding Investigator Award (OIA) (R35 Clinical Trial Not Allowed)

This program requires an Internal Vetting Process.

Internal submission deadline: Wednesday, September 9, 2020

See Internal Submission Guidelines for more details.


Dr. Steve Artandi, the Director of the Stanford Cancer Institute, has established the following vetting process for all Stanford faculty interested in applying for this NCI OIA Award. Dr. Artandi will set up an internal review committee to review potential applications, which will be judged on the basis of a NIH biosketch with current funding and a 1-2 page outline of background and specific aims for a proposal.

Although the number of applications per institution is not limited, applications must be vetted locally and a two page Letter of Nomination signed by Dr. Artandi is required. Institutional support for the faculty member's effort is also mandated. Applications that are missing a Letter of Nomination will not be reviewed by NCI.


Stanford Cancer Institute internal vetting process deadline: Wednesday, September 9, 2020 
Notification of selection and to proceed with a letter of intent: September 23, 2020
For PIs given the approval to proceed with their full applications:
NIH letter of intent deadline (30 days prior to the application deadline): October 7, 2020
Institutional representative (RPM/RMG or CGO/OSR) deadline: October 30, 2020
Application receipt deadline: November 6, 2020

 Program Guidelines

NIH program announcement: PAR-20-278

 Amount of Funding

This R35 award will provide up to $600,000 direct costs (plus indirects) per year for up to 7 years.


Stanford faculty with PI eligibility (UTL, MCL, and NTLR appointments)

  • Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding cancer research productivity during the last 5 consecutive calendar years.
  • The Institution-nominated PD/PI must have been a PD/PI or Project Leader of a research project, excluding cores, (of a NIH-defined multi-project grant e.g., P01, P50, U54) on an eligible NCI research grant(s) continuously since September 2015. Continuous funding is defined as receiving a Notice of Award as PD/PI for an eligible NCI funded research grant in each Federal Fiscal Year beginning in FY 2015 onward. Continuous funding does not include grants in a funded or unfunded extension. Eligible NCI research grant mechanisms are defined as R01, R15, R33, R35, R37, P01, P50, U01, U54, UM1, U19, U10, DP1, and DP2.
  • Due to the nature of this award, applicants are required to devote at least 6 person months effort to the OIA. Applicants with administrative responsibilities or other duties inconsistent with this time commitment may apply but must reduce those other commitments to accept the award.
  • PDs/PIs with effort on other grant support will be expected to provide, as part of the Just-in-Time information, a detailed explanation describing how effort on his/her other grants will be adjusted, if necessary, to permit 6 person months on the OIA.
  • PD/PIs will need to renegotiate their time and effort on other grant support, if necessary, in order to accommodate the OIA level of effort.


In addition, grantee Institutions are expected to:

  • Provide clear and continuing substantial commitment to the PD/PI, for example providing at least 20% salary support for the duration of the award.
  • For New (Type 1) applications; agree to relinquish the PD/PI's existing NCI funded single PD/PI and single project research grants to allow them to be consolidated into the OIA.

 Purpose and Award Details

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques.  Candidates for the OIA must be nominated by their applicant organization.

 Internal Submission Guidelines

By September 9, 2020, please submit one PDF file containing the following, in the order listed below, via email attachment to:

Gayle White
Stanford Cancer Institute

File name: Last name_ Last name_NCI_OIA.pdf

Institutional representative: not applicable. You do not need to submit your internal proposal through your institutional official for approval. You may submit your internal proposal directly to Gayle White.

1) Title page
NCI Outstanding Investigator Award (PAR-20-278)
PI name, title, department, email address

2) Research Proposal
1-2 page outline of background and specific aims for the full proposal.

3) NIH Biosketch
With current and recent funding included.

Selection process:
A small committee at the Stanford Cancer Institute led by Dr. Artandi will decide which proposals should go forward based on merit. They will select the applicants to represent Stanford University.


For inquiries regarding the internal selection process, please contact:

Gayle White
Stanford Cancer Institute